A man with a prolactin secreting pituitary carcinoma was treated by surgery and radiotherapy. Persistent hyperprolactinaemia partially responded to oral bromocriptine for four years. Serum prolactin then rose considerably with rapid, invasive tumour recurrence. Cytotoxic chemotherapy halted tumour progression for twelve months before fatal spread throughout the brain. Failure to normalise serum...

New-onset type II diabetes mellitus, hyperosmolar non-ketotic coma, rhabdomyolysis and acute renal failure in a patient treated with sulpiride Sir, Various drugs have been reported to cause myoglobinuric acute renal failure [1–4]. In this report, we present a case of oral sulpiride administration, complicated with new-onset type II diabetes mellitus, hyperosmolar non-ketotic coma, rhabdomyolysi...

Bromocriptine mesylate quick release formulation has recently been approved by FDA for the treatment of diabetes mellitus. Till now it has been mainly known for its use in Parkinsonism and for suppression of lactation. Present study evaluates and compares the antihyperglycemic effect of the combination of bromocriptine and metformin with either of the two drugs taken alone. For this fasting blo...

INTRODUCTION Bromocriptine, an ergot derivative, is an agonist at the dopamine 2 receptor and a sympatholytic. It is a well established drug in Parkinsonism, hyperprolactinaemia and acromegaly and it has various other clinical indications like induction of ovulation in female infertility. Bromocriptine has been evaluated in alloxan induced diabetic rats for its anti-hyperglycaemic effect with a...

Bromocrriptine is a drug introduced in the medical therapeutics in 1967, and since then it has been widely used in the treatment of hyperprolactinaemia. In experimental animals and in vitro experiments it inhibits prolactin secretion and the phasic secretion of gonadotrophins, while it does not seem to have an effect on growth hormone, or vasopressin secretion. Various central nervous effects, ...

Negative symptoms are still a major obstacle in the recovery of schizophrenic patients. Many attempts to develop novel drugs affecting negative symptoms of schizophrenia have yielded insignificant results. This study evaluates the effects of bromocriptine, a dopamine agonist, on negative symptoms of schizophrenia utilizing a placebo-controlled crossover double-blind clinical trial. Methodology:...

The pituitary gland has only recently been studied with magnetic resonance (MR) imaging. Initial results suggest MR may have utility in the detection and follow-up of pituitary microadenomas [1]. Of interest, it has been observed that prolactinomas treated with bromocriptine may manifest distinct and diverse MR signal changes [1] . Bromocriptine, a dopamine agonist, has been effective in the sy...

One of the most important causes of anticancer treatment failure is the development of multidrug resistance (MDR). The main characteristics of tumor cells displaying the MDR phenomena are cross-resistance to structurally unrelated cytotoxic drugs having different mechanisms of action and the overexpression of the MDR1 gene, which encodes a transmembrane glycoprotein named P-glycoprotein (P-gp)....

A technique has been developed to investigate [3H]sulpiride binding in rat brain sections using quantitative autoradiography and tritium-sensitive film. Binding was saturable and reversible with very low nonspecific binding. [3H]Sulpiride bound to an apparent single population of sites in striatum with a Kd of 3.2 nM and Bmax of 447 fmol/mg protein. Binding sites were localized in the lamina gl...

Little is known about the function of microRNAs in prolactinomas treated with bromocriptine. The aim of the study was to explore the microRNAs associated with bromocriptine-treated prolactinomas. Six prolactinoma samples were selected according to whether they received bromocriptine treatment or not before microsurgery, and microRNA expression pro...